Cargando…
Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery
The aim of this work was to develop niosomes for the ocular delivery of epalrestat, a drug that inhibits the polyol pathway and protects diabetic eyes from damage linked to sorbitol production and accumulation. Cationic niosomes were made using polysorbate 60, cholesterol, and 1,2-di-O-octadecenyl-3...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142600/ https://www.ncbi.nlm.nih.gov/pubmed/37111732 http://dx.doi.org/10.3390/pharmaceutics15041247 |
_version_ | 1785033651957792768 |
---|---|
author | Kattar, Axel Quelle-Regaldie, Ana Sánchez, Laura Concheiro, Angel Alvarez-Lorenzo, Carmen |
author_facet | Kattar, Axel Quelle-Regaldie, Ana Sánchez, Laura Concheiro, Angel Alvarez-Lorenzo, Carmen |
author_sort | Kattar, Axel |
collection | PubMed |
description | The aim of this work was to develop niosomes for the ocular delivery of epalrestat, a drug that inhibits the polyol pathway and protects diabetic eyes from damage linked to sorbitol production and accumulation. Cationic niosomes were made using polysorbate 60, cholesterol, and 1,2-di-O-octadecenyl-3-trimethylammonium propane. The niosomes were characterized using dynamic light scattering, zeta-potential, and transmission electron microscopy to determine their size (80 nm; polydispersity index 0.3 to 0.5), charge (−23 to +40 mV), and shape (spherical). The encapsulation efficiency (99.76%) and the release (75% drug release over 20 days) were measured with dialysis. The ocular irritability potential (non-irritating) was measured using the Hen’s Egg Test on the Chorioallantoic Membrane model, and the blood glucose levels (on par with positive control) were measured using the gluc-HET model. The toxicity of the niosomes (non-toxic) was monitored using a zebrafish embryo model. Finally, corneal and scleral permeation was assessed with the help of Franz diffusion cells and confirmed with Raman spectroscopy. Niosomal permeation was higher than an unencapsulated drug in the sclera, and accumulation in tissues was confirmed with Raman. The prepared niosomes show promise to encapsulate and carry epalrestat through the eye to meet the need for controlled drug systems to treat the diabetic eye. |
format | Online Article Text |
id | pubmed-10142600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101426002023-04-29 Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery Kattar, Axel Quelle-Regaldie, Ana Sánchez, Laura Concheiro, Angel Alvarez-Lorenzo, Carmen Pharmaceutics Article The aim of this work was to develop niosomes for the ocular delivery of epalrestat, a drug that inhibits the polyol pathway and protects diabetic eyes from damage linked to sorbitol production and accumulation. Cationic niosomes were made using polysorbate 60, cholesterol, and 1,2-di-O-octadecenyl-3-trimethylammonium propane. The niosomes were characterized using dynamic light scattering, zeta-potential, and transmission electron microscopy to determine their size (80 nm; polydispersity index 0.3 to 0.5), charge (−23 to +40 mV), and shape (spherical). The encapsulation efficiency (99.76%) and the release (75% drug release over 20 days) were measured with dialysis. The ocular irritability potential (non-irritating) was measured using the Hen’s Egg Test on the Chorioallantoic Membrane model, and the blood glucose levels (on par with positive control) were measured using the gluc-HET model. The toxicity of the niosomes (non-toxic) was monitored using a zebrafish embryo model. Finally, corneal and scleral permeation was assessed with the help of Franz diffusion cells and confirmed with Raman spectroscopy. Niosomal permeation was higher than an unencapsulated drug in the sclera, and accumulation in tissues was confirmed with Raman. The prepared niosomes show promise to encapsulate and carry epalrestat through the eye to meet the need for controlled drug systems to treat the diabetic eye. MDPI 2023-04-14 /pmc/articles/PMC10142600/ /pubmed/37111732 http://dx.doi.org/10.3390/pharmaceutics15041247 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kattar, Axel Quelle-Regaldie, Ana Sánchez, Laura Concheiro, Angel Alvarez-Lorenzo, Carmen Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery |
title | Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery |
title_full | Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery |
title_fullStr | Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery |
title_full_unstemmed | Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery |
title_short | Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery |
title_sort | formulation and characterization of epalrestat-loaded polysorbate 60 cationic niosomes for ocular delivery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142600/ https://www.ncbi.nlm.nih.gov/pubmed/37111732 http://dx.doi.org/10.3390/pharmaceutics15041247 |
work_keys_str_mv | AT kattaraxel formulationandcharacterizationofepalrestatloadedpolysorbate60cationicniosomesforoculardelivery AT quelleregaldieana formulationandcharacterizationofepalrestatloadedpolysorbate60cationicniosomesforoculardelivery AT sanchezlaura formulationandcharacterizationofepalrestatloadedpolysorbate60cationicniosomesforoculardelivery AT concheiroangel formulationandcharacterizationofepalrestatloadedpolysorbate60cationicniosomesforoculardelivery AT alvarezlorenzocarmen formulationandcharacterizationofepalrestatloadedpolysorbate60cationicniosomesforoculardelivery |